Table of Contents Table of Contents
Previous Page  372 / 812 Next Page
Information
Show Menu
Previous Page 372 / 812 Next Page
Page Background

S368

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

2

Research Unit of Clinical Alcohol Research, University of Southern

Denmark, Odense, Denmark

3

Orthopaedic Department, Odense University Hospital, Odense,

Denmark

Corresponding author.

Introduction

Exercise addiction is characterized by increasing

exercise amounts, withdrawal symptoms and lack of control. Exer-

cisers with addiction continue to exercise in spite of pain and injury

because they use exercise to regulate emotions, identity and self-

esteem. How do they react to injuries?

Objectives

It is hypothesized that exercise addiction is a risk fac-

tor for emotional distress when an injury occur due to withdrawal

symptoms and lack of identity.

Aims

To estimate the prevalence of exercise addiction in exer-

cisers with injuries at the musculoskeletal system and to test the

relationship between addiction and emotional distress (depression

and stress).

Methods

The Exercise Addiction Inventory was used to identify

exercise addiction. To measure depression and stress we used the

Major Depression Inventory (MDI) and the Perceived Stress Scale

(PSS). Participants (

n

= 694) were regular exercisers with injuries at

foot, knee or shoulder at an orthopedic hospital department.

Results

The prevalence of exercise addiction was 7.6%. We found

that exercisers with addiction reported more emotional distress in

terms of higher MDI-scores 18.0 (SD = 11.0) versus 11.7 (SD = 9.1);

P

= 0.00 and in total PSS-score 17.6 (SD = 7.2) versus 13.9 (SD = 6.8);

P

= 0.00. Chi

2

analyses showed that 25% of the addicted exercisers

met the criteria for clinical depression, while only 11% of the non-

addicted exercisers were depressed;

P

= 0.00.

Conclusions

Exercisers with addiction appear at somatic depart-

ments treating musculoskeletal injuries. It is a vulnerable group

characterized by elevated levels of depressive symptoms and clin-

ical stress. We recommend to offer psychological interventions

focusing on emotional distress and prevention of re-injury by

reducing excessive and obsessive exercise patterns.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1042

EV58

Qualitative study of patients with dual

pathology in treatment with

aripiprazole extended-release

injectable suspension

L. Fernández Mayo

, D. Ba˜no Rodrigo , E. Barbero García ,

M. Agujetas Rodriguez

CAID Majadahonda, Center for Attention to drug addicts,

Majadahonda, Madrid, Spain

Corresponding author.

Introduction

Studies describe patients with dual pathology as

subjects with worse clinical evolution and worse therapeutic

response. These subjects have high percentages of worse thera-

peutic compliance and low adherence to psychopharmacological

treatment. The conventional antipsychotics can induce dyspho-

ria and worse craving and drug use. The long duration-injectable

antipsychotics could serve as a good therapeutic alternative

because they combine efficacy and tolerability.

Objectives

We analyzed subjects treated with aripiprazole

injectable to demonstrate its effectiveness on symptomatology, the

reduction of craving and consumption of substances.

Materials and methods

We studied subjects with dual disorders

at a Center for Attention to drug addicts treated with aripiprazole

extended-release injectable. All of them met criteria for the diag-

nosis of disorders for cannabis and cocaine use. All of them had

been previously treated with oral antipsychotics and/or injectable

of long duration. Evolution of craving and consumption were eval-

uated through clinical interviews and urine analysis.

Results

Cannabis was the main substance for all the patients.

Three of them also often abused of cocaine. All of themwere taking

other treatments previously. The main causes of the change were:

side effects and/or poor compliance. Only one patient discontinued

follow-up. The rest of them showed good therapeutic adherence

and better tolerability with aripiprazole injectable. The monthly

dose was 400mg.

Conclusions

Aripiprazole extended-release injectable is a good

choice for dual disorders. A good therapeutic adherence involves

not only a psychopathological improvement but also respect to

craving and consumption, which makes aripiprazole injectable a

suitable therapeutic option.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1043

EV59

Nalmefene and alcohol use disorder.

Evaluation of clinical cases at a

treatment centre for drug addicts

L. Fernández Mayo

, D. Ba˜no Rodrigo , E. Barbero García ,

M. Agujetas Rodríguez

CAID Majadahonda, Treatment Centre for Drug Addicts,

Majadahonda, Madrid, Spain

Corresponding author.

Introduction

Alcohol abuse causes dopamine release in the

mesolimbic system, which activates the reward circuit. This is

linked to an interdependent opioid, serotonergic and endocannabi-

noid system. Nalmefene is a modulator of the endogenous opioid

system, with antagonistic effect on mu and delta receptors, and a

partial agonist activity kappa. This means that reduces the reinforc-

ing effects of alcohol consumption through the cortical-mesolimbic

system. Therefore, when a patient takes nalmefene, the satisfaction

obtained when he drinks is lower, which increases the possibility

to have more control over drinking.

The efficacy of nalmefene was evaluated in two profiles of patients:

1. No abstinence in alcohol dependence disorder and continu-

ous relapses, 2. Cocaine dependence disorder associated to alcohol

abuse.

Objectives

Improving the quality of life and compliance rates due

to the difficulties of following a strict treatment to achieve the absti-

nence. Furthermore, in cases of patients with cocaine dependence

disorder and alcohol abuse, the objective is to avoid cocaine use by

reducing previous alcohol consumption.

Conclusion

nalmefene offers the possibility of treating the addic-

tion from a new perspective. Our current clinical experience has

been able to treat subjects with conventional treatments failures

and those who need to achieve the necessary control to reduce

cocaine use.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1044

EV60

Aripiprazole oral treatment in a

sample of patients with dual diagnosis

C. Llanes Álvarez

1 ,

, A. San Román Uría

1

, A. Caldero Alonso

1

,

M.Á. Garzón de Paz

2

, M.Á. Franco Martín

1

1

Complejo Asistencial de Zamora, Psiquiatría, Zamora, Spain

2

Hospital Los Montalvos. Unidad Regional de Patología Dual,

Hospital Universitario de Salamanca, Psiquiatría, Salamanca, Spain

Corresponding author.